Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 20 of 20

Filter Applied: rituximab (Click to remove)

A 60-Year Old Man with Asymmetric Weakness and Persistent Fever
Neurol 100:530-536, Zheng,Y.,et al, 2023

Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008

A 67-Year-Old Woman with Progressive Tingling Sensations and Imlalance
Neurol 100:151-157, Horta,L.F.B.,et al, 2023

Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022

Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016

Neurological disturbances caused by intravascular lymphomatosis
Brain Nerve 63:443-449, Mizutani, T., 2011

Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020

Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018

Clinicopathologic Conference, Granulomatosis with Polyangiitis
NEJM 379:2452-2461, Case 39-2018, 2018

Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017

Treatment Outcomes with Rituximab in 100 Patients with Neuromyelitis Optica
JAMA Neurol 72:989-995, Kim, S.H.,et al, 2015

Rituximab in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Report of 13 Cases and Review of the Literature
JNNP 82:306-308, Benedetti,L.,et al, 2011

Encephalitis Associated with Glutamic Acid Decarboxylase Autoantibodies in a Child A Treatable Condition?
Arch Neurol 68:1065-1068, Korff, C.M.,et al, 2011

Evidence-based Guideline: Clinical Evaluation and Treatment of Transverse Myelitis
Neurol 77:2128-2134, Scott, T.F.,et al, 2011

Posterior Reversible Encephalopathy Syndrome After Rituximab Infusion in Neuromyelitis Optica
Neurol 74:1471-1473, S�nchez-Carteyron,A., et al, 2010

Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010

B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008

Treatment of Neuromyelitis Optica with Rituximab; Retrospective Analysis of 25 Patients
Arch Neurol 65:1443-1448, Jacob,A.,et al, 2008

Limbic Encephalitis and Variants: Classification, Diagnosis and Treatment
Neurologist 13:261-271, Tuzun,E. &Dalmau,J., 2007

Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
Neurologist 12:171-178, Cree,B., 2006



Showing articles 0 to 20 of 20